Passage Bio appoints Thomas Kassberg as Class I director and Audit Committee member

Passage BIO, Inc.

Appointment effective September 10, 2024; Kassberg also joins Audit Committee.
Kassberg currently Chief Business Officer and EVP at Ultragenyx Pharmaceutical.
Received non-incentive stock options with $90,000 grant date fair value, vesting over three years.
Cash compensation per non-executive director policy plus indemnification agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas Kassberg

Class I director

PASG · Passage BIO, Inc.

Effective: 2024-09-10
Filed: September 10, 2024, 7:59 PM ET

On September 9, 2024, the board of directors (the “ Board ”) of Passage Bio, Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Thomas Kassberg as a Class I director and as a member of the Audit Committee of the Board, effective as of September 10, 2024 (the “ Appointment Date ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Kassberg was appointed as Class I director at Passage BIO, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

On September 9, 2024, the board of directors (the “ Board ”) of Passage Bio, Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Thomas Kassberg as a Class I director and as a member of the Audit Committee of the Board, effective as of September 10, 2024 (the “ Appointment Date ”).

View on SEC.gov

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-098371

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.